Analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Nuvectis Pharma in a note issued to investors on Tuesday, February 25th. HC Wainwright analyst J. Pantginis expects that ...

HC Wainwright reiterated their buy rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a report ...

Fintel reports that on February 27, 2025, HC Wainwright & Co. downgraded their outlook for LAVA Therapeutics N.V.

Fintel reports that on February 26, 2025, HC Wainwright & Co. downgraded their outlook for Geron (NasdaqGS:GERN) from Buy to ...

LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts.

SoundHound AI's speech recognition model "outperformed" Google and OpenAI during Q4 as it announced a new seven-figure energy ...

Fintel reports that on February 24, 2025, HC Wainwright & Co. initiated coverage of Veritone (NasdaqGM:VERI) with a Buy recommendation. As of February 19, 2025, the average one-year price target ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (BRSE:1CG) with a Buy recommendation. There are 575 funds or institutions reporting positions ...

Tuesday, Summit Therapeutics plc (NASDAQ:SMMT), currently trading at $18.84, maintained a Buy rating from H.C. Wainwright, with analysts keeping a steadfast $44.00 price target on the stock.

Pemgarda has a standing emergency use authorization as a prophylaxis for immunocompromised patients, but FDA’s stringent ...

On Tuesday, H.C. Wainwright reaffirmed a positive outlook on OKYO Pharma Ltd. (NASDAQ: OKYO), maintaining a Buy rating and a $7.00 price target. Currently trading at $1.10, with a market ...

A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at IN8bio is a clinical-stage biopharmaceutical company ...